Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...

On March 5, 2025, the U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a ...

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation model. A multifaceted approach is needed to reduce financial barriers to obesity ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Patients have been buying compounded weight loss drugs at lower prices than brand-name medications amid shortages of tirzepatide and semaglutide. (Getty Images) ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in glycated haemoglobin (HbA1c ...

Compounding pharmacies faced a major setback in their case over the FDA’s decision to remove the obesity drug tirzepatide ...

Adults with type 1 diabetes had greater declines in HbA1c and body weight 1 year after being prescribed semaglutide or tirzepatide. Randomized controlled trials are needed to assess efficacy and ...

Patients have been buying compounded weight loss drugs at lower prices than brand-name medications amid shortages of tirzepatide and semaglutide. (Getty Images) ...